Side-by-side comparison of AI visibility scores, market position, and capabilities
Latin American BNPL platform with 500+ merchants for underbanked consumers; $8.5M raised positioning as "Affirm for LATAM" competing for $16B regional installment payment market.
Wibond is a buy-now-pay-later (BNPL) platform serving the Latin American market — providing flexible digital payment solutions and consumer credit to the large underbanked population in Argentina, Brazil, Mexico, and other LATAM markets who lack credit cards or access to traditional financing for consumer electronics, appliances, furniture, and other large purchases. Founded in 2020 in Córdoba, Argentina, Wibond raised $8.5 million in funding and reached $4.5 million in revenue by June 2024, integrated with 500+ merchants including Samsung and Musimundo.\n\nWibond's platform allows shoppers at partner merchants to split purchases into installments — applying for and receiving approval in seconds using alternative credit scoring that incorporates mobile data, purchase history, and behavioral signals rather than requiring a credit bureau score. This enables consumers who are excluded from formal credit to access financing for significant purchases, while merchants gain access to higher average order values and customers who couldn't otherwise afford their products. The BNPL model aligns with the cuotas (installments) payment culture deeply embedded in Latin American consumer behavior.\n\nIn 2025, Wibond competes in the rapidly growing Latin American BNPL market alongside Mercado Crédito (Mercado Libre), Kueski Pay (Mexico), Klar, and global players like Klarna and Affirm entering the region. The Latin American BNPL market is projected to reach $16.2 billion in 2025, driven by the region's large underbanked population (60%+ of Latin Americans lack bank accounts), high smartphone penetration, and the cultural acceptance of installment payments. Wibond's Argentina origin gives it deep understanding of the hyper-inflationary market context where consumers prefer installment financing to protect against currency devaluation. The 2025 strategy focuses on expanding merchant network coverage, growing into Brazil and Mexico (the two largest LATAM markets), and building credit risk models that can profitably serve the thin-file consumer segment.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.